February 6, 2023 News by Mary Chapman Sesh, MS Canada partner to help MS patients with mental health To support the wellness journeys of Canadians living with multiple sclerosis (MS), digital healthcare company Sesh is partnering with MS Canada to provide free, unlimited access to its online mental health platform. The partnership allows patients to participate in virtual therapist-led support groups, and kickstarts research efforts…
July 28, 2022 News by Marta Figueiredo, PhD Calyx, Qynapse to Expand Use of Neuroimaging AI Tools Calyx and Qynapse have joined forces to expand the use of artificial intelligence (AI)-based neuroimaging tools in clinical trials of treatment candidates for conditions affecting the central nervous system (CNS), or the brain and spinal cord. This is expected to help advance therapy development for multiple sclerosis…
June 14, 2022 News by Marta Figueiredo, PhD Find Therapeutics, SATT Conectus Team to Develop New MS Therapy Find Therapeutics and SATT Conectus have joined forces to develop a promising therapy for multiple sclerosis (MS) and optic neuritis based on a new class of compounds that shows the potential to regenerate myelin. Myelin is the fatty protective sheath around nerve fibers that’s progressively lost…
May 10, 2022 News by Marta Figueiredo, PhD Biogen, MedRhythms Working on Music Therapy for MS Gait Issues Biogen has entered a licensing agreementĀ to develop and potentially commercialize MedRhythms‘Ā investigational music-based digital therapy, MR-004, designed to help make walking easier for people with multiple sclerosis (MS). The partnership combines Biogenās leadership and expertise in MS with MedRhythmsā digital therapeutics platform that uses sensors, algorithms, and music…
December 1, 2021 News by Patricia Inacio, PhD Deal Brings AI-powered MRI to Care of Patients With Brain Disorders A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the diagnosis and care of patients with multiple sclerosis (MS) and other neurological diseases. Under the partnership, Arterys will include Combinosticsā AI-powered cNeuro on its medical imaging cloud AI platform…
June 14, 2021 News by Patricia Inacio, PhD Shepherd Center, BurnAlong Open Global Online Rehab Classes for MS BurnAlong and theĀ Shepherd Center, a leading rehabilitation hospital in the U.S., have established a partnership to bring tailored rehabilitation classes to people withĀ multiple sclerosis (MS) and other neuromuscular diseases worldwide. The video classes, designed by clinicians, therapists, and wellness professionals at the Shepherd Center, based in Atlanta,…
December 4, 2019 News by Mary Chapman National MS Society Establishes Partnership with Jon Strum’s ‘RealTalk MS’ Podcast When Jon Strum began his āRealTalk MSā podcast two years ago, he did not imagine he soon would have thousands of regular listeners in more than 60 countries. Now, Strum’s popular online audio series has a new partner: the National Multiple Sclerosis Society (NMSS). Strum uses his weekly…
January 8, 2019 News by Iqra Mumal, MSc Biogen and Skyhawk Partner to Develop Small Molecule Therapies for Neurological Diseases BiogenĀ and Skyhawk Therapeutics have created a strategic partnership that will allow both companies to use Skyhawk’s SkySTARĀ technology platform for the discovery of new small molecule treatments for neurological diseases, including multiple sclerosis and spinal muscular atrophy. Under the terms of the agreement, Biogen will be given…
April 13, 2018 News by Patricia Silva, PhD MS Foundation Partnering with ThermApparel to Provide Cooling Vests to Patients The MS Focus: Multiple Sclerosis FoundationĀ will be accepting applications through June for itsĀ Cooling Program, which providesĀ cooling garments to multiple sclerosisĀ patients whose condition has left them heat-sensitive. AlthoughĀ 60 to 80 percent of patients are heat-sensitive, there were no MS-specific cooling garments on the U.S. market until…
March 7, 2018 News by Diogo Pinto Novartis, Pear Collaborating on Digital Therapeutics to Treat MS, Schizophrenia Novartis and Pear Therapeutics are joining forces to develop novel prescription digital therapeutics to treat patients with schizophrenia and multiple sclerosis (MS). Digital therapeutics are software applications designed to treat diseases and improve clinical outcomes for patients.Ā Combining Novartisā expertise in biomedical research and clinical development with Pearās…